Belite Bio, Inc is a clinical stage biopharmaceutical drug development company based in San Diego, CA. They are focused on advancing novel therapies to address the unmet medical needs of patients suffering from blindness, liver disease, and diabetes, with a particular emphasis on retinal degenerative eye diseases such as atrophic age-related macular degeneration (AMD) and Stargardt disease. Their lead candidate, Tinlarebant, is a novel oral therapy designed to reduce the accumulation of toxins in the eye that cause these conditions.
With a strong pipeline of therapies built on their RBP4 Retinol Binding Protein 4 IP Portfolio, Belite Bio is dedicated to bringing hope to those with incurable blindness and metabolic diseases. They have received Fast Track Designation, Rare Pediatric Disease designation, and Orphan Drug Designation for Tinlarebant, highlighting its potential as a groundbreaking treatment for Stargardt disease and Geographic Atrophy. Through their ongoing clinical trials, Belite Bio aims to provide effective and safe solutions for patients in need.
Generated from the website